Sandip Agarwala

Founded in 2007 by Stephen Evans-Freke and Peter Corr, Auven Therapeutics Management LLLP is a global private equity firm located in St. Thomas, Virgin Islands. They also have operations in New York City and Europe. The firm was formerly known as Celtic Therapeutics Management, which was the successor firm to Celtic Pharma Management LP.

Cydan II, Inc. develops and commercializes drugs for orphan and diseases. The firm evaluates products for treating rare diseases with high unmet medical need to start multiple companies to develop such therapies. The company was founded by Cristina Csimma, James G. McArthur, Deborah S. Geraghty and Christoph M. Adams in 2013 and is headquartered in Cambridge, MA.

Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company, which engages in the development of allogeneic hematopoietic stem cell transplantation. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Wellesley, MA.

Blue Owl Credit Advisors LLC (Blue Owl Credit Advisors) is a private equity subsidiary of Blue Owl Capital, Inc founded in 2015 by Douglas Ostrover, Marc Lipschultz and Craig W. Packer. The firm headquartered in New York.

CrownWheel Partners LLC engages in the provision of structure financing solutions with healthcare companies, academic institutions, and inventors. It focuses on the monetization of royalty streams, revenue participation, and purchase of structured debt and equity. The company was founded by Sandip K. Agarwala in 2013 and is headquartered in Greenwich, CT.

Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA.

Opna-IO LLC provides biotechnology services. The company is headquartered in New York, NY.

Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation.

Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland.